It is well known that the Homo sapiens LIM homeobox domain 6 gene (hLHX6), a putative transcription regulator, controls the differentiation and development of neural and lymphoid cells, particularly in the central nervous system. In this study, we investigated hLHX6.1 (an isoform of hLHX6), which functions as a tumor suppressor gene in the cervix. Firstly, the methylation levels of the hLHX6 and hLHX6.1 promoters were investigated in 8 cervical cancer cell lines and human tissue samples with a distinctive degree of malignant transformation. In spite of the presence of multiple cytosine guanine dinucleotides (CpG islands) in 2 proximal promoters of the hLHX6 and hLHX6.1 genes, only the hLHX6.1 promoters were found to be mostly hypermethylated and associated with transcriptional silencing by promoter methylation, whereas the hLHX6 promoters were not. Methylation levels in the hLHX6.1 promoter were also found to be strongly related to cervical cancer development. The level of hLHX6.1 gene expression was found to be relatively high in normal cells, in which the hLHX6.1 promoter was mostly unmethylated. However, the hLHX6.1 gene expression was down-regulated or undetectable in cervical cancer cell lines and cancer tissues, in which the hLHX6.1 promoter was hypermethylated. This epigenetic alteration in the hLHX6.1 promoter begins at a relatively early stage, suggesting its potential as a biomarker for the early diagnosis and prevention of cervical cancer. Moreover, the overexpression of the hLHX6.1 gene in cervical cancer cells suppressed the tumorigenic phenotype, as shown by soft agar colony formation and migration assays, suggesting that hLHX6.1 could be a new tumor suppressor gene in the cervix.
Introduction
Cervical cancer is the second most frequent malignant type of cancer worldwide and is still an important health issue for women. When infected by the human papillomavirus (HPV), a major cause of cervical cancer, the cervical epithelium develops an invasive cervical carcinoma via a multistep process (1) (2) (3) (4) . Multistep cervical carcinogenesis can be classified into 5 groups: Normal, cervical intraepithelial neoplasia (CIN) I (mild dysplasia), CIN II (moderate dysplasia), CIN III (severe dysplasia) and invasive cervical carcinoma (5) (6) . Persistent HPV infection accelerates the development of CINs by facilitating the dysregulation of cellular proliferation and the apoptotic process. In spite of its strong association with cervical cancer, HPV infection alone is not sufficient for the cervical epithelium to fully develop an invasive carcinoma. Additional accumulation of mutations in various genes is required before these premalignant lesions develop into invasive ones. These mutations include the overexpression of oncogenes or the repression of tumor suppressor genes. Among them, promoter hypermethylation is one of the main causes for the inactivation of the transcription of tumor suppressor genes (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The epigenetic silencing of various genes by promoter hypermethylation is now recognized as a frequent event in the pathogenesis of many cancers, including cervical cancer. An abnormal pattern of DNA methylation occurs at specific genes in nearly all neoplasms, making DNA methylation of special interest as a tumor biomarker (16) (17) (18) . High densities of CpG sites are found in many homeobox genes and some of them are found to be highly methylated (19) . Homeobox genes encode transcription factors and play vital roles in embryogenesis, the differentiation of adult cells and related developmental processes (20) . Among many homeobox genes, the human genome contains at least 12 LIM homeobox (LHX) genes encoding LIM homeo domain transcription factors. These genes usually have a LIM domain in addition to a homeo domain. The LIM domain, a unique cytosine-rich zinc-binding domain, is used for the interaction with an LIM domain-binding protein (Ldb) that negatively regulates the transcriptional activity of many LHX proteins (21) (22) . Studies with mouse models and human patients have shown that LHX proteins play important roles in cytoskeletal organization, organ development and oncogenesis. LHX proteins are known to be involved in human diseases (23) (24) (25) .
It is well known that the human LHX6 gene, hLHX6, controls the differentiation and development of neural and lymphoid cells, particularly in the central nervous system (CNS) (26) (27) (28) (29) (30) . The hLHX6 gene is considered to be a putative transcription factor required for the expression of genes involved in interneuron migration and development. Two alternatively spliced transcript variants have been found for this gene, hLHX6a and hLHX6b. Besides these 2 transcripts, another isoform of LHX6.1 was first found in a mouse model, as reported by Kimura et al (31) . They suggested that the LHX6.1 gene is closely related to the LHX6 gene that is expressed predominantly in the developing CNS. They showed that LHX6.1 interacts with Ldb1 through tandem LIMdomains like other LHX proteins, implying the transcriptional regulation of LHX6.1 by Ldb1 (31) . In addition, hLHX6s, an alternative short isoform of the hLHX6 gene, was identified by Estecio et al (32) . However, the biological functions of this transcript variant have not yet been determined. While the hLHX6 gene is significantly expressed in many tissues, the gene expression of hLHX6s has only been detected in a few tissues. In spite of these advanced studies, little information is available on the molecular mechanisms that regulate the transcription of the hLHX6 and hLHX6.1 genes. Particularly, gene regulation by hypermethylation on hLHX6.1 gene expression has not been previously investigated in any cancers including cervical cancer. In the process of developing a methylation DNA biomarker for the early diagnosis of cervical cancer, we previously showed that the hLHX6-hypermethylated region, which includes the genomic sequences found between exons 4a and 5 of the hLHX6s, is a sensitive methylation-based molecular biomarker with increased sensitivity and specificity for the early diagnosis of cervical cancer (33) . CpG islands are also found in 2 proximal promoters of the hLHX6 and hLHX6.1 genes. It is a well known fact that transcriptional silencing by promoter hypermethylation is an important regulatory mechanism in many cancer cells. These facts led us to further study the molecular mechanism and roles of the hLHX6.1 gene in cervical cancer development.
In this study, we show that the hLHX6.1 promoter is frequently hypermethylated in cervical cancer cells and that this epigenetic alteration of the hLHX6.1 gene is associated with transcriptional silencing and cancer cell development. More importantly, our present study for the first time provides insight into the mechanism of hLHX6.1 tumor suppression in cervical carcinogenesis.
Materials and methods
Cervical cancer cell lines and human tissue samples. Eight cervical cancer cell lines were used for this study. C33A, CaSki, HeLa and SiHa cells were purchased from the American Type Culture Collection (USA). The other cell lines, SNU-17, -703, -1160 and -1299, were obtained from the Korean Cell Line Bank (KCLB, Korea). Each cell line was grown in one of the following different media: C33A, HeLa and SiHa cells in DMEM medium (WelGENE Inc., Korea), CaSki, SNU-703 and SNU-1299 cells in RPMI-1640 medium (Gibco BRL), and SNU-17 and SNU-1160 in AR5 medium (KCLB). All the media were supplemented with 10% fetal bovine serum (Gibco BRL) and 1% antibiotic-antimycotic solution (Gibco BRL). All the cells were cultured at 37˚C in a humidified atmosphere composed of 95% air and 5% CO 2 . A total of 110 human tissue samples were kindly provided by Dr Chang-Jin Kim at the Soonchunhyang University Hospital (Cheonan, Korea). These tissue samples originated from cervical cancer patients, and their histological tumor grade and age is presented in Table I . The tissue samples for CIN diagnosis were prepared via microexcision. Patients signed informed consent forms and the procedure for obtaining the tissue samples was approved by the institutional review board of the hospital clinic.
Reverse transcription (RT)-PCR.
Following the manufacturer's instructions, total RNA was extracted from the cervical cancer cell lines or human tissue samples using the RNeasy mini kit (Qiagen). For reverse transcription, 1 μg RNA of each sample was subjected to cDNA synthesis using oligo(dT) primer and the RevertAid First Strand cDNA Synthesis Kit (Fermentas, Korea) according to the manufacturer's instructions. PCR amplification was performed using 10 ng cDNA, different sets of primers and AccuPower PCR PreMix (Bioneer, Korea). The nucleotide sequences of the primers and the conditions for gene amplification are shown in Table II . As the internal control, the 377-bp ß-actin gene products were amplified using pRT-ACTB-forward (F) and -reverse (R) primers. The amplification reaction was carried out using the GeneAmp PCR System 9700 from Applied Biosystems. The amplification products were electrophoresed on a 2% agarose gel stained with ethidium bromide. The band intensity was visualized and measured using a UV illuminator or a LAS-3000 imaging system.
Methylation-specific PCR (MSP) and bisulfite sequencing PCR (BSP) analyses.
Genomic DNA was extracted from the cervical cancer cell lines or human tissue samples using the DNeasy Blood and Tissue Kit (Qiagen). A bisulfite treatment was conducted using 1 μg of genomic DNA at 55˚C for 16 h following the instructions included with the EZ DNA Methylation Kit (Zymo Research, CA, USA). For MSP analysis, the bisulfite-treated DNA samples underwent PCR amplification using 2 pairs of primers, which were designed to amplify unmethylated or methylated targets. The nucleotide sequence of each primer and the amplification conditions are shown in Table II . For all MSP analyses, the PCR mixtures contained 10X reaction buffer, dNTP mixture (1 mM), primers (final concentration of 10 pmole per reaction), 1 unit of HotStart prime Taq (Qiagen) and bisulfitetreated DNA. The amplification products were resolved in 2% agarose gels and stained with ethidium bromide. The methylation status was inferred by the presence or absence of bands and its density was represented by the thickness of the bands. For BSP analysis, the bisulfite-treated DNA samples underwent a PCR reaction using the corresponding primer pairs, pBSP-LHX6-F/pBSP-LHX6-R for amplification of the hLHX6 promoter and pBSP-LHX6.1-F/pBSP-LHX6.1-R for the LHX6.1 promoter (Table II) . All the BSP primers are designed to cover the transcriptional start site or be close to the transcriptional start site. The amplified PCR products were cloned into the pBlueScript-SK(+) vector using HindIII and EcoRI restriction enzymes and were transformed into DH5· competent cells. Plasmids purified from amphicillinpositive colonies were sequenced using the M13-F or -R primer by Solegent (Daejeon, Korea).
Treatment of 5'-aza-2'-deoxycytidine (DAC) and trichostatin A (TSA).
Cells from 5 cervical cancer cell lines (HeLa, SiHa, SNU-17, SNU-703 and SNU-1299) were treated with a DNA demethylating agent of DAC (Sigma) and/or a histone deacetylase inhibitor of TSA (Sigma). The cells were plated onto 100-mm plates for 24 h before treatment. They were then treated with 1, 3, 5, or 10 μM of DAC for 24, 48, 72, or 96 h. The cells were also treated with 0.1, 0.3, 0.5, or 1 μM of TSA for 24 or 48 h.
Construction of pcDNA3-hLHX6.1. For the functional study of the hLHX6.1 protein, the hLHX6.1 overexpressing vector, pcDNA3-hLHX6.1, was constructed as follows: The full Table I . Human cervical tissue samples used in RT-PCR, MSP and BSP analyses. 
length of hLHX6.1 cDNA was amplified using the primer set, pLHX6.1-BamHI/pLHX6.1-EcoRI (Table II) , and the pME18SFL3 plasmid as a template. The pME18SFL3 plasmid containing the hLHX6.1 cDNA [NITE Biological Resource Center (NBRC) clone no. AK313808] was obtained from the NBRC (www.nbrc.nite.go.jp/e/). Amplified PCR products were cloned into pcDNA3 using BamHI and EcoRI restriction enzymes to generate the pcDNA3-hLHX6.1 plasmid.
Soft agar colony forming and wound healing migration assays. SiHa cells were transfected with 0.4 μg of pcDNA3-hLHX6.1 plasmid using the Lipofectamine™ reagent (Gibco) according to the manufacturer's instructions. A pcDNA3 plasmid without the hLHX6.1 gene was also transfected as the control. For transient transfection, SiHa cells were treated with G418 and the clones were pooled. Overexpression of the hLHX6.1 protein was verified by Western blotting. For this process, the hLHX6 antibody was purchased from Santa Cruz (sc-81970, Santa Cruz Biotechnology). For the soft agar colony forming assay, the cells were then counted, diluted and seeded in duplicate at 50 cells per culture dish (6-well plate). The cells were incubated for 26 h at 37˚C. Colonies were allowed to grow for 13 days. They were counted after staining with 1% Giemsa solution. For the wound healing assay, SiHa cells (1x10 5 ) were plated onto 60-mm tissue culture dishes and allowed to create a confluent monolayer. Cells were grown for 48 h after transfection with pcDNA3 or pcDNA3-hLHX6.1. The cell monolayer was then scraped in a straight line to make a 'scratched wound' with a 0.2 ml pipette tip, and the cell debris was removed by washing the cells with phosphate-buffered saline. DMEM medium supplemented with 10% FBS and G418 were then added and the closure of the scratch was photographed at 0, 24 and 48 h.
Statistical analysis. Statistical analyses were carried out with the Statistical Package of the Social Sciences (SPSS) software. The association of the hLHX6.1 promoter methylation with cervical carcinogenesis was determined using the Chisquare (or ¯2) test. Statistical significance was set at a P-value of <0.05. -
Results
Transcriptional levels of hLHX6, hLHX6.1 and hLHX6s genes in 8 cervical cancer cell lines. The genomic structure of all known hLHX6 isoforms (hLHX6, hLHX6.1 and hLHX6s) is shown in Fig. 1A , in which they are mapped to chromosome 9p32. The full lengths of their cDNA are shown in Fig. 1B . The hLHX6 and hLHX6.1 transcripts basically contain 10 and 9 exons, respectively. Both genes have 2 types of alternatively spliced isoforms, hLHX6a and hLHX6b, and hLHX6.1a and hLHX6.1b. Nucleotide sequences were obtained from the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST/). RT-PCR was employed to measure the transcriptional level of the hLHX6, hLHX6.1 and hLHX6s genes in 8 cervical cancer cell lines using corresponding primer sets (see Materials and methods; Fig. 1B and C) . The results showed that a relatively high level of gene expression was detected in the SNU-1299 cell line, whereas low levels were detected in other cell lines when the hLHX6 isoforms were tested together (Fig. 1C) . A similar expression level was detected when the hLHX6.1 gene was tested alone. However, no transcript of the hLHX6s gene was detected in any of the cervical cancer cell lines. Therefore, we could not exclude the possibility that hLHX6s is not normally expressed in the cervix, as was also the case in the study by Estecio et al (32) . This hypothesis was confirmed by testing for hLHX6s gene expression in normal cervix tissue samples (data not shown). On the whole, the results indicate that the transcription of the hLHX6 and hLHX6.1 genes is normally repressed in most cervical cancer cell lines.
The methylation status of hLHX6 and hLHX6.1 promoters in 8 cervical cancer cell lines. It has been reported that transcriptional silencing by promoter hypermethylation is an important regulatory mechanism in many tumors. We therefore examined the DNA methylation status of the hLHX6 and hLHX6.1 promoters. Putative CpG islands in 2 promoter regions of the hLHX6 and hLHX6.1 genes were predicted using the MethPrimer program (http://www.urogene.org// methprimer) (34) , with the default setting (%GC>50%, ObsCpG/ExpCpG>0.6). A much higher frequency of CpG dinucleotides was found in the hLHX6 and hLHX6.1 promoters compared to the hLHX6s promoter ( Fig. 2A) . The CpG island searcher program revealed CpG islands spanning the whole region of the genes, hLHX6 and hLHX6.1 (data not shown). Considering the high frequency of CpG sites in the hLHX6 and hLHX6.1 promoters and the low transcriptional level of the hLHX6 and hLHX6.1 genes, it is likely that the low expression of the hLHX6 and hLHX6.1 genes in cervical cancer cells results from DNA methylation in the hLHX6 and hLHX6.1 promoters. To test this hypothesis, MSP and BSP assays were employed to investigate the methylation status in the hLHX6 and hLHX6.1 promoters (see Materials and methods). Initially, MSP assay was performed using primers designed to amplify unmethylated or methylated DNA targets. The MSP results showed that only unmethylated bands were detected in the hLHX6 promoters of most cervical cancer cell lines except for the CaSki and HeLa cells, in which both unmethylated and methylated PCR products were amplified with similar densities (Fig. 2B) . Methylated PCR products were dominantly amplified from the hLHX6.1 promoters (Fig. 2B) . These results suggest that the hLHX6.1 promoter is preferentially targeted for DNA methylation in cervical cancer cell lines. The accuracy of the MSP method in detecting methylated DNA was verified by BSP assay. The bisulfited DNA samples were amplified using corresponding primer sets for hLHX6 and hLHX6.1 (see Materials and methods). Consistent with the results from the MSP assay, the BSP analysis demonstrated that the hLHX6.1 promoters were hypermethylated in all tested cell lines although relatively low levels of methylation were found in C33A and SNU-1299 cell lines. The hLHX6 promoters were not methylated in most cell lines but were found to be hypermethylated in the CaSki and HeLa cell lines (Fig. 2C) .
On the whole, these results indicate that DNA methylation is common in the hLHX6.1 promoter but not in the hLHX6 promoter of cervical cancer cell lines. The RT-PCR, MSP and BSP analyses showed an inverse relationship between hLHX6.1 gene expression and promoter methylation. The transcriptional levels of the hLHX6.1 gene were found to be low in cervical cancer cell lines that have a hypermethylated hLHX6.1 promoter. Therefore, the effect of the hLHX6.1 promoter methylation on its gene expression was further investigated.
Recovery of hLHX6.1 gene expression by treatment with DAC and TSA.
Our results implied that hypermethylation in the hLHX6.1 promoter could be responsible for the transcriptional silencing of the hLHX6.1 gene in cervical cancer cell lines. To test this hypothesis, hLHX6.1 gene expression was measured after treatment with DAC and/or TSA (see Materials and methods). Consistent with our hypothesis, hLHX6.1 gene expression was reactivated by drug treatment in the HeLa, SiHa, SNU-17 and SNU-703 cell lines (Fig. 3) . Treatment with DAC increased hLHX6.1 expression in most tested cell lines. Treatment with DAC and TSA together significantly increased hLHX6.1 gene expression (Fig. 3) . As expected, no significant change was observed in the SNU-1299 cell line, in which considerable expression was detected both before and after the treatment. These results suggest that hLHX6.1 promoter hypermethylation is associated with the transcriptional silencing of the hLHX6.1 gene in cervical cancer cell lines.
Inverse relationship between hLHX6.1 promoter methylation and hLHX6.1 gene expression during multistep cervical carcinogenesis. The hLHX6.1 promoter hypermethylation in cervical cancer cell lines suggested the possibility of the same situation in vivo. Therefore, this investigation was extended to human tissue samples that were collected from 5 different stages of cervical cancer development: A normal cervix, CIN I, II and III, and invasive carcinoma. Initially, the methylation level of both the hLHX6 and hLHX6.1 promoters was evaluated in a total of 110 cervical tissues samples. The MSP analysis showed that unmethylated PCR products were dominantly amplified from hLHX6 promoters in all tissue samples (Fig. 4A) . In contrast, the methylation level in the hLHX6.1 promoter increased as normal cells developed into cancer cells. Non-methylated or partially methylated hLHX6.1 promoters were found in normal and CIN I tissue samples, whereas a high degree of methylation was observed in CIN III and invasive carcinoma (Fig. 4A) . We validated the reliability of MSP analysis by performing BSP assay. Certain hLHX6 and hLHX6.1 methylationnegative or -positive cervical cancers were selected for BSP analysis. Five or 8 clones from representative samples were sequenced to evaluate the methylation levels of the hLHX6 and hLHX6.1 promoters. None of the tissue samples exhibited hypermethylation of the hLHX6 promoter (Fig. 4B) . Very low levels of methylation were found in the hLHX6.1 promoter from normal, and CIN I and II tissue samples, whereas high levels of methylation were observed in CIN III and invasive carcinoma cells (Fig. 4B) . Importantly, abnormal DNA methylation in the hLHX6.1 promoter occurs at CIN I, a relatively early stage of multistep carcinogenesis. This finding suggests that hLHX6.1 promoter methylation is correlated with cervical cancer development. This fact proposes the potential clinical application of hLHX6.1 methylation as an important molecular biomarker in the early diagnosis and prevention of cervical cancer. hLHX6.1 gene expression was also measured in normal and cervical cancer tissues to test whether the hLHX6.1 expression level is related to cervical cancer development (Fig. 4C) . RT-PCR was used to check the hLHX6.1 gene expression level using pRT-hLHX6-2-F and -R primers. The hLHX6.1 transcript was well expressed in normal tissue samples while it was undetectable in most invasive carcinoma cells, where a high degree of methylation was found in the hLHX6.1 promoter (Fig. 4C ). An unexpected observation was 2 PCR products of different sizes, a relatively large PCR product and the expected PCR product, which was considered to be an alternatively spliced transcript (Fig. 4C) . However, this requires additional testing.
Overall, the hLHX6.1 gene expression is shown to be frequently silenced in cervical cancer cells. DNA methylation analyses and RT-PCR revealed an inverse relationship between the hLHX6.1 promoter methylation and its gene expression. Furthermore, hypermethylation of the CpG-rich hLHX6.1 promoter was only found in carcinoma cells and not in normal cervical tissues, suggesting that it most likely represents a tumor-associated event that occurs during cervical cancer development. This fact implies that the hLHX6.1 gene could be a potential tumor suppressor gene. Therefore, our hypothesis was further tested using functional assays.
Functional study of hLHX6.1 by soft agar colony formation and migration assays. This study shows that the methylation level of the hLHX6.1 promoter increases as normal cells develop into cervical cancer, in which hLHX6.1 gene expression is repressed, partly due to promoter hypermethylation. It is well known that the transcription of many key tumor suppressor genes is found to be inactivated by promoter hypermethylation in many cancer cells. These facts imply that hLHX6.1 could act as a tumor suppressor gene in Figure 3 . Effect of the demethylating agents, DAC and/or TSA on hLHX6.1 gene expression. RT-PCR was carried out using cDNA from each cell line which was subjected to different concentrations of the drug treatments and pRT-LHX6-2-F and -R primers (see Materials and methods).
the cervix. Therefore, soft agar colony formation assay was used to examine the tumor suppression ability of the hLHX6.1 gene (see Materials and methods). 
C
( Fig. 5A and B) . The hLHX6.1 overexpression suppressed the colony-forming ability by at least 75% (P<0.01). These results suggest that hLHX6.1 exerts a tumor suppressive effect on cervical cancer cells. The pcDNA3-hLHX6-transfected SiHa cells were able to express comparable levels of hLHX6.1 protein, which was confirmed by Western blot analysis (Fig. 5C) . In order to investigate whether hLHX6.1 expression is involved in cervical cancer cell migration, we performed a wound healing migration assay. The pcDNA3 transfected SiHa cells migrated and covered the scratch after 48 h, whereas a significant area of the scratch remained uncovered in the pcDNA3-hLHX6.1-transfected SiHa cells, suggesting that the overexpression of the hLHX6.1 gene inhibits the wound healing of SiHa cells (Fig. 5D) . The exogenous expression of hLHX6.1 in the SiHa cell line exhibiting hypermethylation in the hLHX6.1 promoter significantly decreased motility in vitro, indicating the involvement of hLHX6.1 in cell migration. On the whole, these findings show that the hLHX6.1 expression could affect cell growth and migration in cervical cancer cells.
Discussion
Our investigation into the methylation level of the hLHX6 and hLHX6.1 promoters showed that only the hLHX6.1 promoter was preferentially hypermethylated in cervical cancer cells despite the presence of multiple CpG sites in both promoters. The hypermethylation of the hLHX6.1 promoter is crucial for its transcriptional silencing. It was of special interest that the hLHX6.1 gene expression was detected in normal human cervical tissue cells despite the fact that it is a well-known brain region-specific gene product. Unexpectedly, the hLHX6 gene expression level was also repressed despite the fact that its promoter was not methylated in most cervical cancer cell lines. This result implies that the hLHX6 gene expression could be under the control of another transcriptional regulation system, rather than epigenetic regulation by promoter methylation. Studies on the hLHX3 gene have shown that the cell-specific expression of 2 transcripts of hLHX3 is driven by the 2 different regulatory systems of epigenetic and genetic mechanisms (35) . Considering that they belong to the same family, it is plausible to assume that the hLHX6 gene expression could be regulated in a similar manner. In other words, the hLHX6 gene expression could be regulated by a transcriptional factor in a genetic regulation, while hLHX6.1 gene expression is under the control of epigenetic regulation. However, we could not exclude the possibility that hLHX6.1 could be regulated by both genetic and epigenetic regulations. Hence, attempts to predict the possible transcription factors involved in the genetic regulation of the hLHX6 and hLHX6.1 genes, were made using the TRANSFAC database (http://www.genome.ad.jp). Putative motifs of MZF1 and Sp1 were found in both hLHX6 and hLHX6.1 promoters. The binding sites of MZF1, Sp1 and AP-4 were dominantly found in the hLHX6 promoter and the binding sites of MZF1, Sp1, USF and E2F1 were found in the hLHX6.1 promoter (data not shown). Our data show the role of hLHX6.1 as a potential tumor suppressor gene in the cervix. Other LHX genes have also been implicated in tumorigenesis. Choi et al showed that inactivated LHX8 reduces the transcription of the proapoptotic genes, Bax, Casp2 and Casp3 in mouse oocytes (36). Thus, hLHX6.1 could function as a tumor suppressor gene by regulating the activity of the pro-apoptotic protein in the cervix. Therefore, the transcriptional levels of the Bax and Casp2 genes were measured in hLHX.6.1 overexpressing HeLa and SiHa cervical cancer cells. However, no significant difference was detected between the control and hLHX6.1 overexpressing cells at the transcriptional level (data not shown). Vladimirova et al showed that the LHX9 gene is frequently silenced in pediatric malignant astrocytomas by hypermethylation and that this epigenetic alteration is involved in glioma cell invasiveness and migration (25) . This is consistent with our data that hLHX6.1 overexpressing cells suppressed cell migration (Fig. 5) . These results imply that hLHX6.1 could play a significant role in cell migration. They also showed that the exogenous expression of LHX9 in glioma cell lines did not directly affect cell proliferation. In contrast, according to a colony formation assay, our present results show that hLHX6.1 overexpressing cells suppress cell proliferation (Fig. 5) . On the whole, these discrepant results imply that hLHX6.1 could play a different role in cancer cells despite the fact that it belongs to the same LHX family.
Our study led us to conclude the following: Firstly, that the transcription of both the hLHX6 and hLHX6.1 genes is repressed in cervical cancer cells. However, their gene expression is under the control of different regulatory systems. Transcriptional silencing by promoter methylation is associated only with the hLHX6.1 gene expression, not with the hLHX6 gene expression in cervical cancer cells. Secondly, that the methylation level in the hLHX6.1 promoter increases as normal cells develops into cervical cancer. This epigenetic alteration begins at a relatively early stage, suggesting its potential as a biomarker for the early diagnosis of cervical cancer, and thirdly, that hLHX6.1 functions as a tumor suppressor gene in the cervix. This study on hLHX6.1 provides insight into the mechanism of hLHX6.1 tumor suppression.
